Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?

Core Insights - The fourth-quarter earnings season for the biotech sector is currently underway, with several major companies reporting results, including Bristol Myers, Regeneron, and Amgen, all of which showed varying degrees of performance and outlooks for 2025 [1] Biotech Sector Performance - As of February 5, 39.3% of companies in the Medical sector reported quarterly earnings, with 87.5% beating earnings expectations and 83.3% exceeding revenue forecasts. Year-over-year earnings increased by 20.1%, while revenues grew by 9% [3] - The overall expectation for the Medical sector's fourth-quarter earnings is an increase of 11.1% year over year, with revenues projected to grow by 9% [3] Company-Specific Insights Bristol Myers - Reported better-than-expected fourth-quarter results but provided a lackluster guidance for 2025 [1] Regeneron - Beat fourth-quarter earnings and sales expectations and initiated a quarterly dividend [1] Amgen - Delivered decent fourth-quarter results, beating both earnings and sales expectations, but faced investor disappointment due to a regulatory setback for its obesity drug [1] Vertex Pharmaceuticals - Vertex has beaten earnings estimates in three of the last four quarters, with an average surprise of 3.26%. The company is expected to report fourth-quarter earnings on February 10, with consensus estimates of $2.77 billion in sales and$3.99 per share in earnings [5][6][7] Gilead Sciences - Gilead has also beaten earnings expectations in three of the last four quarters, with an average surprise of 15.46%. The consensus estimates for fourth-quarter sales and earnings are $7.06 billion and$1.66 per share, respectively. The company is set to report results on February 11 [8][9][10] Biogen - Biogen has beaten expectations in three of the last four quarters, with an average surprise of 9.99%. The consensus estimates for fourth-quarter sales and earnings are $2.42 billion and$3.42 per share, respectively. Biogen will report results on February 12 [11][12] Alnylam Pharmaceuticals - Alnylam has beaten estimates in three of the last four quarters, with an average surprise of 65.67%. The consensus estimates for sales and earnings are $570.1 million and a loss of$0.21 per share, respectively. Alnylam is set to report results on February 13 [13][14] Moderna - Moderna has consistently beaten earnings estimates, with an average surprise of 72.65%. The consensus estimates for fourth-quarter sales and earnings are $956.11 million and a loss of$2.65 per share, respectively. The company is expected to report results on February 14 [15][16]